Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination

被引:3
|
作者
van den Biggelaar, Anita H. J. [1 ]
Richmond, Peter C. [2 ]
Fuery, Angela [2 ,5 ]
Anderson, Denise [1 ]
Opa, Christine [3 ]
Saleu, Gerard [3 ]
Lai, Mildred [3 ]
Francis, Jacinta P. [3 ]
Alpers, Michael P. [4 ]
Pomat, William S. [3 ]
Lehmann, Deborah [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia
[3] Papua New Guinea Inst Med Res, Goroka, Eastern Highlan, Papua N Guinea
[4] Curtin Univ, Sch Hlth Sci, Int Hlth, Perth, WA, Australia
[5] Baylor Coll Med, Houston, TX 77030 USA
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
英国医学研究理事会; 英国惠康基金; 澳大利亚国家健康与医学研究理事会;
关键词
RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; HYPORESPONSIVENESS; IMMUNOGENICITY; DISEASE; PERSISTENCE; 7-VALENT; EFFICACY; BOOSTER;
D O I
10.1371/journal.pone.0185877
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Trial design In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3-5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5 th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3-5 years of age for a subgroup of study children. Results Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers similar to 0.35 mu g/ml and similar to 1.0 mu g/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3-5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3-5 years of age between the three groups. Conclusions Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6-18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Bennett, Nancy M.
    Pilishvili, Tamara
    Whitney, Cynthia G.
    Moore, Matthew
    Gierke, Ryan
    Harris, Aaron M.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2013, 62 (25): : 521 - 524
  • [32] Nasopharyngeal carriage of Streptococcus pneumoniae among children <5 years of age in Indonesia prior to pneumococcal conjugate vaccine introduction
    Safari, Dodi
    Daningrat, Wa Ode Dwi
    Milucky, Jennifer L.
    Khoeri, Miftahuddin Majid
    Paramaiswari, Wisiva Tofriska
    Tafroji, Wisnu
    Salsabila, Korrie
    Winarti, Yayah
    Soebandrio, Amin
    Hadinegoro, Sri Rezeki
    Prayitno, Ari
    Childs, Lana
    Pimenta, Fabiana C.
    Carvalho, Maria da Gloria
    Pilishvili, Tamara
    Melo-Cristino, Jose
    Melo-Cristino, Jose
    Melo-Cristino, Jose
    Melo-Cristino, Jose
    Melo-Cristino, Jose
    PLOS ONE, 2024, 19 (01):
  • [33] Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening
    Hardie, R.
    King, L.
    Fraser, R.
    Reid, M.
    ANNALS OF TROPICAL PAEDIATRICS, 2009, 29 (03): : 197 - 202
  • [34] Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6-17 years
    Mitchell, Ruth
    Trueck, Johannes
    Pollard, Andrew J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (10) : 1451 - 1465
  • [35] Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children <5 years in Cameroon, 2011-2018
    Libwea, John Njuma
    Fletcher, Mark A.
    Ndombo, Paul Koki
    Boula, Angeline
    Ashukem, Nadesh Taku
    Baleba, Madeleine Ngo
    Bebey, Rachel Sandrine Kingue
    Mviena, Eric Gaston Nkolo
    Tageube, Jean
    Mbollo, Marie Kobela
    Koulla-Shiro, Sinata
    Madhi, Shabir
    Njanpop-Lafourcade, Berthe-Marie
    Mohammad, Ali
    Begier, Elizabeth
    Southern, Joanna
    Beavon, Rohini
    Gessner, Bradford
    PLOS ONE, 2021, 16 (04):
  • [36] Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2-5 years in China
    Wang, Jian
    Bai, Shuang
    Zhou, Shanshan
    Zhao, Wei
    Li, Qin
    Lv, Min
    Zhang, Peng
    Zhang, Haizhou
    Lan, Wenwen
    Kang, Yanli
    Wang, Yali
    Li, Jin
    Gao, Xiaotong
    Tong, Xiaomei
    Wu, Jiang
    Zheng, Qun
    VACCINE, 2021, 39 (25) : 3428 - 3434
  • [37] Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil
    de Rezende, Rodrigo Poubel Vieira
    Oliveira-Santos, Marise
    Andrade, Luis Eduardo Coelho
    Klumb, Evandro Mendes
    LUPUS, 2023, 32 (05) : 694 - 703
  • [38] Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran
    Ezoji, Khadijeh
    Yaghoubi, Mohsen
    Nojomi, Marzieh
    Mahmoody, Sussan
    Zahraie, Seyed Mohsen
    Moradi-Lakeh, Maziar
    Tabatabaei, Sedigheh R.
    Karimi, Abdollah
    EASTERN MEDITERRANEAN HEALTH JOURNAL, 2019, 25 (10) : 686 - 697
  • [39] Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years-Zimbabwe, 2010-2016
    Dondo, Vongai
    Mujuru, Hilda
    Nathoo, Kusum
    Jacha, Vengai
    Tapfumanei, Ottias
    Chirisa, Priscilla
    Manangazira, Portia
    Macharaga, John
    de Gouveia, Linda
    Mwenda, Jason M.
    Katsande, Regis
    Weldegebriel, Goitom
    Pondo, Tracy
    Matanock, Almea
    Lessa, Fernanda C.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 : S72 - S80
  • [40] Revaccination with a 23-Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ≥65 Years
    Manoff, Susan B.
    Liss, Charles
    Caulfield, Michael J.
    Marchese, Rocio D.
    Silber, Jeffrey
    Boslego, John
    Romero-Steiner, Sandra
    Rajam, Gowrisankar
    Glass, Nina E.
    Whitney, Cynthia G.
    Carlone, George M.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (04) : 525 - 533